Saigo Chiemi, Iinuma Koji, Kameyama Koji, Mizutani Kosuke, Nakano Masahiro, Kito Yusuke, Takeuchi Tamotsu
Department of Pathology and Translational Research, Gifu University Graduate School of Medicine Gifu, Japan.
Department of Urology, Gifu University Graduate School of Medicine Gifu, Japan.
Int J Clin Exp Pathol. 2018 Mar 1;11(3):1754-1757. eCollection 2018.
Plasmacytoid urothelial carcinoma (PUC), a morphological variant of urothelial carcinoma (UC), is composed of cancer cells that resemble plasma cells, monocytes, or both, and is clinicopathologically distinguished by its aggressive, non-organ-confined features. Here, we present a case of a patient with PUC with early invasion at diagnostic transurethral resection. Histopathologically, no residual cancer or lymph node metastasis was observed by total cystectomy. The patient remains disease-free after 18 months, without undergoing adjuvant chemotherapy. Interestingly, the immunoreactivity of MET, a receptor tyrosine kinase expressed in many invasive UCs, was minimal in the cancer cells. In contrast, archival pathological, non-organ-confined PUC cells exhibited strong MET immunoreactivity. The present case may imply a role for the MET protein in the aggressive behavior of PUCs. We propose the putative usefulness of MET inhibitors for the treatment of aggressive PUCs.
浆细胞样尿路上皮癌（PUC）是尿路上皮癌（UC）的一种形态学变异型，由类似于浆细胞、单核细胞或两者皆有的癌细胞组成，其临床病理特征为具有侵袭性、非器官局限性。在此，我们报告一例在诊断性经尿道切除时发现早期浸润的PUC患者。组织病理学检查显示，全膀胱切除术后未观察到残留癌或淋巴结转移。该患者在未接受辅助化疗的情况下，18个月后仍无疾病复发。有趣的是，在许多浸润性UC中表达的受体酪氨酸激酶MET在癌细胞中的免疫反应性很低。相比之下，存档的病理标本中，非器官局限性PUC细胞表现出强烈的MET免疫反应性。本病例可能提示MET蛋白在PUC侵袭行为中发挥作用。我们提出MET抑制剂对侵袭性PUC治疗可能具有潜在效用。
